<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-499" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chemotherapy Acral Erythema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chidharla</surname>
            <given-names>Anusha</given-names>
          </name>
          <aff>UICOMP</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kanderi</surname>
            <given-names>Tejaswi</given-names>
          </name>
          <aff>UPMC Pinnacle</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anusha Chidharla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tejaswi Kanderi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-499.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or Burgdorf reaction. It is caused by classic chemotherapeutic agents and newer molecular targeted therapies and characterized by intense, painful erythema of the palms and soles that can progress to vesicles or bullae. This activity discusses the proper identification of the condition and adequate management. This activity highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of palmar-plantar erythrodysesthesia.</p></list-item><list-item><p>Describe the exam findings typically seen in patients with palmar-plantar erythrodysesthesia.</p></list-item><list-item><p>Describe the potential complications of palmar-plantar erythrodysesthesia.</p></list-item><list-item><p>Describe the modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by palmar-plantar erythrodysesthesia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=499&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=499">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-499.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acral erythema, also known as Palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, toxic erythema of the palms and soles,&#x000a0; hand-foot syndrome (HFS), or&#x000a0;Burgdorf reaction.&#x000a0;This adverse event is caused by many classic chemotherapeutic agents and newer molecular-targeted therapies. It is characterized by intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae.<xref ref-type="bibr" rid="article-499.r1">[1]</xref><xref ref-type="bibr" rid="article-499.r2">[2]</xref><xref ref-type="bibr" rid="article-499.r3">[3]</xref>. See <bold>Image.</bold>&#x000a0;Chemotherapy Acral Erythema.</p>
      </sec>
      <sec id="article-499.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Doxorubicin (most common with pegylated lysosomal preparation), cytarabine, docetaxel, capecitabine, or 5-fluorouracil (mostly infusional regimen) are the most frequently implicated agents<xref ref-type="bibr" rid="article-499.r1">[1]</xref><xref ref-type="bibr" rid="article-499.r4">[4]</xref>.</p>
        <p>Other drugs causing acral erythema are bleomycin, cisplatin, cyclophosphamide, daunorubicin, doxifluridine, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ixabepilone, methotrexate, mitotane, paclitaxel, tegafur, thiotepa, and vinorelbine.<xref ref-type="bibr" rid="article-499.r5">[5]</xref><xref ref-type="bibr" rid="article-499.r6">[6]</xref><xref ref-type="bibr" rid="article-499.r7">[7]</xref><xref ref-type="bibr" rid="article-499.r8">[8]</xref>.</p>
        <p>It is also postulated that genetic polymorphisms of enzymes involved in the metabolism of some fluoropyrimidines like Capecitabine are the culprit in developing PPE&#x000a0;<xref ref-type="bibr" rid="article-499.r9">[9]</xref></p>
        <p>PPE seems to be dose-dependent, and both peak drug concentration and total cumulative dose determine its occurrence.&#x000a0;Drug formulation and administration schedules that result in sustained serum levels of cytotoxic agents are more frequently associated with acral erythema<xref ref-type="bibr" rid="article-499.r10">[10]</xref><xref ref-type="bibr" rid="article-499.r11">[11]</xref><xref ref-type="bibr" rid="article-499.r1">[1]</xref>.</p>
        <p>Multitargeted tyrosine kinase inhibitors and others that target angiogenesis are associated with hand-foot skin reactions (This is not discussed in the current article). However, clinical and histologic patterns differ from the typical acral erythema that develops with standard cytotoxic agents.</p>
      </sec>
      <sec id="article-499.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>&#x000a0;Overall Incidence of HFS is not well documented. However, the incidence of developing HFS in patients treated with capecitabine is around 60%.</p>
      </sec>
      <sec id="article-499.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathogenesis is not very well understood. Researchers think that the accumulation of chemotherapeutic drugs in eccrine glands, which are more numerous in palms and soles, may cause eccrine squamous syringometaplasia (ESS). ESS&#x000a0;is characterized by metaplasia and focal necrosis of the epithelium of the eccrine duct. ESS is occasionally detected in conjunction with acral erythema, but such occurrences are relatively uncommon.</p>
        <p>Data suggests that Capecitabine (fluoropyrimidine) toxicity may be associated with genetic polymorphisms of&#x000a0;dihydropyrimidine&#x000a0;dehydrogenase (DPYD) and thymidylate synthase (TYMS), enzymes involved in its metabolism<xref ref-type="bibr" rid="article-499.r9">[9]</xref>. Data also suggest that palmar skin has a high expression of&#x000a0;capecitabine-activating enzyme thymidine phosphorylase leading to a high concentration of active component levels <xref ref-type="bibr" rid="article-499.r12">[12]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-499.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologic changes include dermatitis with necrotic and dyskeratotic keratinocytes, dermal edema, vacuolar degeneration and perivascular lymphocytic infiltrate<xref ref-type="bibr" rid="article-499.r5">[5]</xref>. However, the biopsy is not usually done promptly for diagnostic purposes.</p>
      </sec>
      <sec id="article-499.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The condition typically begins with dysesthesias like a tingling sensation in the palms and/or soles and produces symmetric, well-demarcated painful erythema that can&#x000a0;progress to blistering with desquamation, erosion, and ulceration.&#x000a0;An especially severe bullous variant that advances to full-thickness epidermal necrosis and sloughing has been reported following&#x000a0;cytarabine or high-dose intravenous&#x000a0;methotrexate, particularly in children.</p>
        <p>Although rare, acral erythema involving the penis and scrotum has been reported.</p>
        <p>A presumed variant of acral erythema, called fixed erythrodysesthesia plaque (FEP), is characteristic of intravenous (IV) injections of&#x000a0;docetaxel. This lesion develops as a fixed, single plaque, proximal to the infusion site, which does not include the palms or soles. It resolves with desquamation and leaves an area of hyperpigmented skin in 5 to 6 weeks.</p>
        <p>Temporary Loss of fingerprint is seen with capecitabine-associated,&#x000a0;chronic acral erythema and can cause identification issues.</p>
      </sec>
      <sec id="article-499.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Painful red swelling of the feet and hands in a patient receiving chemotherapy suggests the&#x000a0;diagnosis. A high degree of suspicion is the key to diagnosis in patients receiving chemotherapeutic agents. The problem may also occur&#x000a0;in patients with bone marrow transplants, as the clinical and histologic features may mimic cutaneous manifestations of graft-versus-host disease.</p>
        <p>Dangerous graft-versus-host disease must be differentiated&#x000a0;from benign palmar-plantar&#x000a0;erythrodysesthesia. Patients with graft-versus-host disease will have progression to other body parts whereas PPE will be limited to hands and feet. Serial biopsies every 3 to 5 days may help&#x000a0;in differentiating the two disorders.<xref ref-type="bibr" rid="article-499.r5">[5]</xref></p>
      </sec>
      <sec id="article-499.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The mainstay of treatment is the discontinuation of the drug and symptomatic treatment to provide pain relief, decrease edema, and prevent superinfection. Symptomatic treatment includes wound care, alcohol-free emollients, elevation, and pain medication.&#x000a0; Healing includes superficial desquamation of affected areas. Often chemotherapy dose intensity modification or reduction is needed if the drug cannot be&#x000a0;discontinued or substituted&#x000a0;for&#x000a0;another cancer drug or cancer treatment.</p>
        <p>Usually, it resolves within 2 to 4 weeks of drug cessation.&#x000a0;</p>
        <p>In the case of severe (grade 3) acral erythema, further chemotherapy doses should be reduced to prevent a recurrence. Depending on overall clinical status switching to an alternative regimen may be necessary if the risk of recurrence is thought to be high.&#x000a0;</p>
      </sec>
      <sec id="article-499.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Graft versus host disease (GVHD)</p>
          </list-item>
          <list-item>
            <p>Steven johnson syndrome (SJS)</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis (TEN)</p>
          </list-item>
          <list-item>
            <p>Fixed drug eruption</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-499.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>HFS is dose-related. The treatment for HFS is dose modification or drug interruption.</p>
        <p>HFS resolves within two to four weeks of discontinuation of the chemotherapy. In patients who are getting capecitabine, topical urea 10% cream can be used for the prevention of HFS from capecitabine.</p>
        <p>For severe grade 3 HFS, subsequent doses of chemotherapy need to be reduced.&#x000a0;</p>
      </sec>
      <sec id="article-499.s12" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Regional cooling using ice packs to wrists and ankles during therapy may help in decreasing the frequency and severity of symptoms by decreasing blood flow&#x000a0;<xref ref-type="bibr" rid="article-499.r13">[13]</xref><xref ref-type="bibr" rid="article-499.r14">[14]</xref>. It is usually a well-tolerated prevention strategy.</p>
        <p>Randomized clinical trials using topical urea preparation to&#x000a0;hands and feet revealed contradictory results depending on the dosage and duration of treatment in patients receiving capecitabine. Further studies need to validate the use to be applied in clinical practice<xref ref-type="bibr" rid="article-499.r15">[15]</xref><xref ref-type="bibr" rid="article-499.r16">[16]</xref>.&#x000a0;</p>
        <p>Studies including meta-analysis conducted using pyridoxine (Vitamin B6) reveal varying results<xref ref-type="bibr" rid="article-499.r17">[17]</xref><xref ref-type="bibr" rid="article-499.r18">[18]</xref><xref ref-type="bibr" rid="article-499.r19">[19]</xref></p>
        <p>Oral&#x000a0; Celecoxib&#x000a0;200 to 400 mg twice a day for 12 to 18 weeks significantly reduced the risk of grades 2 and 3 HFS (odds ratio 0.37, 95% CI 0.19-0.71) in a meta-analysis of randomized trials<xref ref-type="bibr" rid="article-499.r20">[20]</xref>. However, celecoxib is known for its potential cardiovascular adverse effects with long-term use and upper gastrointestinal (GI) risk of bleeding. The benefit-to-risk ratio is not favorable for the extensive use of celecoxib for the prevention or treatment of HFS&#x000a0;<xref ref-type="bibr" rid="article-499.r3">[3]</xref>.</p>
        <p>Studies using systemic corticosteroids in the management of HFS are also not convincing resulting in the need for large randomized clinical trials<xref ref-type="bibr" rid="article-499.r21">[21]</xref></p>
      </sec>
      <sec id="article-499.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Tyrosine kinase inhibitors like sunitinib, sorafenib, bevacizumab which target angiogenesis are also associated with hand-foot skin reaction (HFSR) which is different from HFS from conventional chemotherapy. Studies have shown that HFSR showed an association with tumor response and overall survival.&#x000a0;<xref ref-type="bibr" rid="article-499.r22">[22]</xref>&#x000a0;Combined use of chemotherapy and&#x000a0; TKI has increased in the recent past. It is crucial to differentiate the side effects between side effects from both the agents to guide the reduction in the appropriate therapy if needed. HFS from cytotoxic chemotherapy causes diffuse erythema and desquamation compared to hyperkeratotic lesions in HSFR.&#x000a0;</p>
      </sec>
      <sec id="article-499.s14" sec-type="Staging">
        <title>Staging</title>
        <p>According to the national cancer institute, common terminology criteria for adverse events (NCI CTCAE version 5), Grading of Severity of HFS is classified as follows</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade 1:&#x000a0;</bold>Minimal skin changes or dermatitis (e.g., erythema or edema) without pain</p>
          </list-item>
          <list-item>
            <p><bold>Grade 2</bold>:&#x000a0;Skin changes (e.g., peeling, blisters, bleeding, or hyperkeratosis) with pain leading to limitation of instrumental activities of daily living (ADL)</p>
          </list-item>
          <list-item>
            <p><bold>Grade 3</bold>:&#x000a0;Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting basic self-care ADL <xref ref-type="bibr" rid="article-499.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-499.s15" sec-type="Complications">
        <title>Complications</title>
        <p>PPE can cause a significant impact on a patient's quality of life. There are usually no long-term after-effects; however, palmoplantar keratoderma may develop as a result of long-standing acral erythema.&#x000a0;Fingerprint loss is reversible after treatment discontinuation.</p>
      </sec>
      <sec id="article-499.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Acral erythema is also known as palmar-plantar erythrodysesthesia (PPE), palmoplantar erythrodysesthesia, hand-foot syndrome (HFS), or&#x000a0;Burgdorf reaction.&#x000a0;This is an adverse event caused by many classic chemotherapeutic agents and newer molecular targeted therapies. It is an intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae. Healthcare professionals should be familiar with acral erythema while managing patients on chemotherapy. The condition is best managed by an interprofessional team that includes the dermatologist, oncologist, oncology nurse, pharmacist, and primary care provider. Patients and families need to be educated about the condition to be vigilant in monitoring the symptoms. When the condition is diagnosed, depending on the overall clinical condition and severity of symptoms decisions regarding decreasing the dose or discontinuation of treatment need to be made with shared decision making.&#x000a0;</p>
        <p>Regional cooling with ice packs around wrists and ankles is a well-tolerated strategy with no side effects and should be tried. There is a need for large randomized controlled trials to formulate appropriate management options to treat the condition effectively. Overall, the quality of life is poor if the condition is not adequately treated [Level V]<xref ref-type="bibr" rid="article-499.r5">[5]</xref>.</p>
      </sec>
      <sec id="article-499.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=499&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=499">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/chemotherapy-acral-erythema-hand-foot-syndrome-toxic-erythema-of-the-palms-and-soles/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=499">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/499/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=499">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-499.s18">
        <fig id="article-499.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Chemotherapy Acral Erythema.&#x000a0; Acral erythema is characterized by intense, painful erythema of the palms and soles that can progress to the formation of vesicles or bullae.&#x000a0;&#x000a0; StatPearls Publishing Illustration</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Chemotherapy_Acral_Erythema-01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-499.s19">
        <title>References</title>
        <ref id="article-499.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dogru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kocaoglu</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Probable cytarabine-induced acral erythema: report of 2 pediatric cases.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>e11</fpage>
            <page-range>e11-3</page-range>
            <pub-id pub-id-type="pmid">22767133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giacchero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Monpoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chiav&#x000e9;rini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lacour</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>[6-mercaptopurine-related hand-foot syndrome in a four-year-old child].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2008</year>
            <season>Aug-Sep</season>
            <volume>135</volume>
            <issue>8-9</issue>
            <fpage>580</fpage>
            <page-range>580-3</page-range>
            <pub-id pub-id-type="pmid">18789293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Degen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schenck</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Satzger</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kapp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gutzmer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The hand-foot-syndrome associated with medical tumor therapy - classification and management.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>652</fpage>
            <page-range>652-61</page-range>
            <pub-id pub-id-type="pmid">20482685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Chidharla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kanderi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kasi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Chemotherapy Acral Erythema</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">29083584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hueso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanmart&#x000ed;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nagore</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Botella-Estrada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Requena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Llombart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Serra-Guill&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alfaro-Rubio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guill&#x000e9;n</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2008</year>
            <month>May</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-90</page-range>
            <pub-id pub-id-type="pmid">18394404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sardana</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bhardwaj</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Methotrexate Cutaneous Toxicity following a Single Dose of 10 mg in a Case of Chronic Plaque Psoriasis: A Possible Idiosyncratic Reaction.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>328</fpage>
            <page-range>328-330</page-range>
            <pub-id pub-id-type="pmid">30258802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jalandhara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaeley</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous toxicity of oral low-dose methotrexate.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>364</fpage>
            <page-range>364-366</page-range>
            <pub-id pub-id-type="pmid">29904314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Amjad</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Chidharla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kasi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Cancer Chemotherapy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">33232037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosmarin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Palles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Love</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Julier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scudder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gonzalez-Neira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sargent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McLeod</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zanger</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lacas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boige</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ribelles</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Enghusen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Etienne-Grimaldi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wadelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glimelius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garmo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gusella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lecomte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laurent-Puig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martinez-Balibrea</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garcia-Foncillas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kleibl</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Midgley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>1031</fpage>
            <page-range>1031-9</page-range>
            <pub-id pub-id-type="pmid">24590654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambichler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strutzmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tannapfel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Susok</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.</article-title>
            <source>BMC Cancer</source>
            <year>2017</year>
            <month>May</month>
            <day>12</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>327</fpage>
            <pub-id pub-id-type="pmid">28499411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caccavale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruocco</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Acral manifestations of systemic diseases: Drug-induced and infectious diseases.</article-title>
            <source>Clin Dermatol</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-63</page-range>
            <pub-id pub-id-type="pmid">27938813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Medenica</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lorincz</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Soltani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raab</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Distinctive acral erythema occurring during therapy for severe myelogenous leukemia.</article-title>
            <source>Arch Dermatol</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-4</page-range>
            <pub-id pub-id-type="pmid">3855356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molpus</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Puleo</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.</article-title>
            <source>Gynecol Oncol</source>
            <year>2004</year>
            <month>May</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>513</fpage>
            <page-range>513-6</page-range>
            <pub-id pub-id-type="pmid">15099971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mangili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petrone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Marzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rabaiotti</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.</article-title>
            <source>Gynecol Oncol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>332</fpage>
            <page-range>332-5</page-range>
            <pub-id pub-id-type="pmid">18083217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delaune</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Christian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pajon</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Satele</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Berenberg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Loprinzi</surname>
                <given-names>CL</given-names>
              </name>
              <collab>North Central Cancer Treatment Group Study N05C5</collab>
            </person-group>
            <article-title>Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <day>10</day>
            <volume>28</volume>
            <issue>35</issue>
            <fpage>5182</fpage>
            <page-range>5182-7</page-range>
            <pub-id pub-id-type="pmid">21060036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofheinz</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gencer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hegewisch-Becker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loeffler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kronawitter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bolz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Potenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tauchert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Al-Batran</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <day>01</day>
            <volume>33</volume>
            <issue>22</issue>
            <fpage>2444</fpage>
            <page-range>2444-9</page-range>
            <pub-id pub-id-type="pmid">26124485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Aug</month>
            <day>20</day>
            <volume>28</volume>
            <issue>24</issue>
            <fpage>3824</fpage>
            <page-range>3824-9</page-range>
            <pub-id pub-id-type="pmid">20625131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalermchai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tantiphlachiva</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suwanrusme</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Voravud</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sriuranpong</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.</article-title>
            <source>Asia Pac J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-60</page-range>
            <pub-id pub-id-type="pmid">20887495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>e72245</fpage>
            <pub-id pub-id-type="pmid">23977264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macedo</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>dos Santos</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Sasse</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.</article-title>
            <source>Support Care Cancer</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>1585</fpage>
            <page-range>1585-93</page-range>
            <pub-id pub-id-type="pmid">24463616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farrar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.</article-title>
            <source>Gynecol Oncol</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-4</page-range>
            <pub-id pub-id-type="pmid">15297168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-499.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sissung</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Danesi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Dahut</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kummar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liewehr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Yarchoan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giaccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Venitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Figg</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.</article-title>
            <source>J Exp Clin Cancer Res</source>
            <year>2010</year>
            <month>Jul</month>
            <day>14</day>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">20630084</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
